Researchers study barriers to GLP-1 insurance coverage
Tuesday, July 21 – Despite growing evidence that GLP-1 medications improve health and are worth their cost, many insurance plans still limit coverage. University of Mississippi researchers are examining why and where that leaves patients.
Ozempic-like drugs found to be safe and effective for children with obesity, without diabetes
Tuesday, July 21 – New research being presented at the International Congress on Obesity (ICO2026), hosted by the World Obesity Federation (WOF) in Mexico City, Mexico (15–17 July), shows that glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for weight loss in children of various ages without diabetes are safe and effective. The study is by Dr. Manpreet Kaur Oberoi of the University of Western Ontario in London, Ontario, Canada, and colleagues.
Q&A: Psychedelics, cannabis, GLP-1s and drug policy changes
Tuesday, July 21 – From headlines and social media, psychedelic therapies, cannabis use and GLP-1 medications have seemingly become commonplace overnight, but the science underlying these treatments and the pathway to drug approval are often more nuanced than the headlines suggest.
Vision Changes, Food Aversions, Mood Swings, And 21 Other Surprising Ways People Say GLP-1 Medications Changed Their Lives Beyond Weight Loss
Monday, July 20 – “I’m the one that has to live in my body, I’m doing what I need to get my life back, and that’s all that matters.”View Entire Post ›
The Upside-Down World of the GLP-1 Bridge
Sunday, July 19 – (MedPage Today) — I spent 10 minutes in complete silence in my patient’s room today, my eyes scanning lines of text in the electronic medical record. I wasn’t looking for a life-threatening lab value or an undiscovered malignancy. I was hunting…
GLP-1 Drugs Like Ozempic, Wegovy May Help With Binge Eating Disorder
Saturday, July 18 – GLP-1 medications like Ozempic and Wegovy may help ease symptoms of binge eating disorder and related eating behaviors. Giselleflissak/Getty Images
A new study found that GLP-1RAs could reduce key symptoms of binge eating disorder.
These included binge eating severity, loss of control eating, and emotional eating.
Experts say that GLP-1RAs could potentially augment existing treatments for binge eating disorder, like psychotherapy.
Why GLP-1 Drugs May Raise Muscle Loss, Frailty Risk for People Over 65
Saturday, July 18 – A new report states that older adults using GLP-1 drugs may have a higher risk of loss of muscle mass, malnutrition, dehydration, and other frailty-associated conditions. Getty Images
A new report states that older adults using GLP-1 drugs may have a higher risk of loss of muscle mass, malnutrition, and dehydration.
However, the benefits of taking these drugs should be weighed against these risks when the medications are prescribed.
Semaglutide and other GLP-1 drugs not linked to risk of degenerative eye disease in adults with type 2 diabetes
Saturday, July 18 – An estimated 27% of U.S. adults with diabetes are using glucagon-like peptide-1 receptor agonists (GLP-1 RAs)—a type of medication that mimics the GLP-1 hormone—to lower blood sugar and support weight loss. Some research has suggested that their use can reduce the risk of developing other diseases.
GLP-1 shows promise for patients with advanced fatty liver disease
Saturday, July 18 – Researchers at the University of California San Diego School of Medicine have reported results from a large international clinical trial showing that semaglutide, a medication in the GLP-1 class of drugs widely used to treat diabetes and obesity, may help reduce liver scarring in patients with advanced fatty liver disease, including those with early-stage cirrhosis.
Compounders maintain a firm grip on the GLP-1 market
Saturday, July 18 – Despite an FDA crackdown and numerous pharma lawsuits, nearly 1 in 5 patients are taking cheaper weight-loss alternatives despite the risks.